Log in

NASDAQ:BSTC - BioSpecifics Technologies Stock Price, Forecast & News

$65.07
-0.51 (-0.78 %)
(As of 02/17/2020 06:00 AM ET)
Today's Range
$64.45
Now: $65.07
$65.87
50-Day Range
$53.99
MA: $58.37
$65.58
52-Week Range
$45.81
Now: $65.07
$73.31
Volume20,638 shs
Average Volume37,881 shs
Market Capitalization$477.61 million
P/E Ratio20.59
Dividend YieldN/A
Beta1.25
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.96 million
Cash Flow$3.09 per share
Book Value$13.41 per share

Profitability

Net Income$20.05 million

Miscellaneous

Employees6
Market Cap$477.61 million
Next Earnings Date4/7/2020 (Estimated)
OptionableNot Optionable

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.


BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) issued its earnings results on Friday, November, 8th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.75 by $0.10. The biopharmaceutical company had revenue of $9.44 million for the quarter, compared to the consensus estimate of $8.86 million. BioSpecifics Technologies had a net margin of 64.23% and a return on equity of 21.82%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 brokers have issued 12-month price targets for BioSpecifics Technologies' shares. Their forecasts range from $90.00 to $90.00. On average, they expect BioSpecifics Technologies' stock price to reach $90.00 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price. View Analyst Price Targets for BioSpecifics Technologies.

What is the consensus analysts' recommendation for BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSpecifics Technologies.

Has BioSpecifics Technologies been receiving favorable news coverage?

News stories about BSTC stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BioSpecifics Technologies.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include Biogen (BIIB), AbbVie (ABBV), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Jazz Pharmaceuticals (JAZZ), Momo (MOMO), NVIDIA (NVDA), Zynerba Pharmaceuticals (ZYNE) and Alibaba Group (BABA).

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Dr. Ronald Law J.D., Ph.D., Interim Principal Exec. Officer (Age 66)
  • Mr. Patrick M. Caldwell, Interim Principal Financial Officer (Age 57)
  • Carl A. Valenstein, Corp. Sec.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.85%), Rice Hall James & Associates LLC (4.75%), Royce & Associates LP (2.33%), Russell Investments Group Ltd. (2.18%), AQR Capital Management LLC (2.11%) and State Street Corp (1.88%). Company insiders that own BioSpecifics Technologies stock include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which institutional investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including THB Asset Management, Royce & Associates LP, Goldman Sachs Group Inc., Chicago Equity Partners LLC, AQR Capital Management LLC, Oxford Asset Management LLP, Marshall Wace LLP and Strs Ohio. Company insiders that have sold BioSpecifics Technologies company stock in the last year include Jennifer M Chao, Mark N Wegman, Patrick M Caldwell, Paul Gitman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies.

Which institutional investors are buying BioSpecifics Technologies stock?

BSTC stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Boston Partners, Bank of Montreal Can, Aviva PLC, Freestone Capital Holdings LLC, Cambridge Investment Research Advisors Inc., Cadence Capital Management LLC and State Street Corp. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $65.07.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $477.61 million and generates $32.96 million in revenue each year. The biopharmaceutical company earns $20.05 million in net income (profit) each year or $2.73 on an earnings per share basis. BioSpecifics Technologies employs 6 workers across the globe.View Additional Information About BioSpecifics Technologies.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is http://www.biospecifics.com/.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  534
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel